---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-24-000036"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:52:13.962122+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q2 revenue $212M (+15% YoY); raises FY2024 guidance, adjusted EPS $0.05

## Summary
- Revenue $212M (+15% YoY); GAAP EPS $(0.41) vs $(1.42) YoY; adjusted EPS $0.05 vs $(0.08).
- Raises FY2024 revenue guidance to $835-$845M (11-12% growth); adj EPS to $0.08-$0.12.
- Prenatal rev +25%, Pharmacogenomics +22%, Hereditary Cancer +19%; Tumor profiling -9% YoY.
- Cross-license with Personalis (PSNL) for MRD patents; GSK collaboration for HRD testing.
- Long-term revenue growth target raised to 12% from prior; total test volume +9% to 389K.

## SEC filing metadata
- accession: 0000899923-24-000036
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992324000036/0000899923-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992324000036/mygn-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-24-000036
- JSON: https://secwatch.observer/filing/0000899923-24-000036.json
- Plain text: https://secwatch.observer/filing/0000899923-24-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.